PT3439660T - Utilização de pimobendan para a redução do tamanho do coração e o retardamento do início de sintomas clínicos em doentes com insuficiência cardíaca assintomática devido a doença da válvula mitral - Google Patents

Utilização de pimobendan para a redução do tamanho do coração e o retardamento do início de sintomas clínicos em doentes com insuficiência cardíaca assintomática devido a doença da válvula mitral

Info

Publication number
PT3439660T
PT3439660T PT177151610T PT17715161T PT3439660T PT 3439660 T PT3439660 T PT 3439660T PT 177151610 T PT177151610 T PT 177151610T PT 17715161 T PT17715161 T PT 17715161T PT 3439660 T PT3439660 T PT 3439660T
Authority
PT
Portugal
Prior art keywords
pimobendan
onset
patients
delay
reduction
Prior art date
Application number
PT177151610T
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PT3439660T publication Critical patent/PT3439660T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT177151610T 2016-06-01 2017-04-04 Utilização de pimobendan para a redução do tamanho do coração e o retardamento do início de sintomas clínicos em doentes com insuficiência cardíaca assintomática devido a doença da válvula mitral PT3439660T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172394 2016-06-01

Publications (1)

Publication Number Publication Date
PT3439660T true PT3439660T (pt) 2024-07-18

Family

ID=56108530

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177151610T PT3439660T (pt) 2016-06-01 2017-04-04 Utilização de pimobendan para a redução do tamanho do coração e o retardamento do início de sintomas clínicos em doentes com insuficiência cardíaca assintomática devido a doença da válvula mitral

Country Status (2)

Country Link
EA (1) EA039250B1 (pt)
PT (1) PT3439660T (pt)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3210605A1 (en) * 2005-11-14 2017-08-30 Boehringer Ingelheim Vetmedica GmbH Use of pde iii inhibitors for the treament of asymptomatic (occult) heart failure

Also Published As

Publication number Publication date
EA039250B1 (ru) 2021-12-23
EA201892226A1 (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
LT3439660T (lt) Pimobendano panaudojimas širdies padidėjimo mažinimui bei klinikinių simptomų pasireiškimo atidėjimui pacientams su besimptomiu širdies nepakankamumu dėl mitralinio vožtuvo ligos
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
JP2016014009A5 (pt)
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
WO2012064301A3 (en) Physically improved tablet formulations
ZA201308391B (en) Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
IL283469A (en) Inhalable preparations for use in the treatment of lung diseases
EP3013425A4 (en) Treatment and diagnosis of ocular disease
LT3124048T (lt) Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui
HK1221177A1 (zh) 用於減少鉀和治療慢性腎病和/或慢性心臟病的微孔矽酸鋯和利尿藥
PT3439660T (pt) Utilização de pimobendan para a redução do tamanho do coração e o retardamento do início de sintomas clínicos em doentes com insuficiência cardíaca assintomática devido a doença da válvula mitral
Ashare et al. D25 PEDIATRIC CYSTIC FIBROSIS: Regional Differences In Hypoxia Induced Angiotensin Ii Impact The Inflammatory Response Of Lung Macrophages In Cystic Fibrosis
EP3386450A4 (en) INDEX FOR QUANTIFYING THE BOWMAN LAYER FOR THE DIAGNOSIS OF DISEASES AND THE PROGNOSIS OF TREATMENTS IN THE HUMAN BONE
GB201616502D0 (en) The use of brain waves as biomarkers for alzheimers disease and combined treatment for early stage diagnosed patients
CN302577455S (zh) 镜片屈光测定仪
TH1501005402A (th) องค์ประกอบซึ่งประกอบรวมด้วยซีลีเนียมและการใช้ดังกล่าวสำหรับการบำบัดและการ ป้องกันโรคหรือสภาวะที่เกี่ยวข้องกับความผิดปกติในการทำงานของไมโตคอนเดรีย
CN301978866S (zh) 低频率治疗器
CN302481181S (zh) 沙发(951#)
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CN302493501S (zh) 沙发(2029#)
CN302481179S (zh) 沙发(2028#)
CN302481180S (zh) 沙发(2027#)
CN302291275S (zh) 马桶